ES2491891T3 - Marcaje celular para técnicas de resonancia magnética nuclear - Google Patents

Marcaje celular para técnicas de resonancia magnética nuclear Download PDF

Info

Publication number
ES2491891T3
ES2491891T3 ES05705450.4T ES05705450T ES2491891T3 ES 2491891 T3 ES2491891 T3 ES 2491891T3 ES 05705450 T ES05705450 T ES 05705450T ES 2491891 T3 ES2491891 T3 ES 2491891T3
Authority
ES
Spain
Prior art keywords
cell
magnetic resonance
nuclear magnetic
resonance techniques
cellular labeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05705450.4T
Other languages
English (en)
Inventor
Eric T. Ahrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carnegie Mellon University
Original Assignee
Carnegie Mellon University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carnegie Mellon University filed Critical Carnegie Mellon University
Application granted granted Critical
Publication of ES2491891T3 publication Critical patent/ES2491891T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules

Abstract

Un método para marcar una célula, el método comprende poner en contacto la célula ex vivo con un reactivo de imagenología de fluorocarbono en condiciones tales que el reactivo de imagenología de fluorocarbono se asocia con la célula, en donde dicha célula marcada se va administrar a un sujeto, en donde dichas células marcadas son detectables por imagenología de resonancia magnética de 19F y en donde dicha célula no es una célula madre embrionaria humana.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES05705450.4T 2004-01-16 2005-01-11 Marcaje celular para técnicas de resonancia magnética nuclear Active ES2491891T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53730304P 2004-01-16 2004-01-16
US537303P 2004-01-16
US62196104P 2004-10-25 2004-10-25
US621961P 2004-10-25
PCT/US2005/000800 WO2005072780A2 (en) 2004-01-16 2005-01-11 Cellular labeling for nuclear magnetic resonance techniques

Publications (1)

Publication Number Publication Date
ES2491891T3 true ES2491891T3 (es) 2014-09-08

Family

ID=34830444

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05705450.4T Active ES2491891T3 (es) 2004-01-16 2005-01-11 Marcaje celular para técnicas de resonancia magnética nuclear

Country Status (7)

Country Link
US (2) US8147806B2 (es)
EP (2) EP1713513B1 (es)
JP (1) JP5019883B2 (es)
AU (1) AU2005209169B2 (es)
CA (1) CA2560544C (es)
ES (1) ES2491891T3 (es)
WO (1) WO2005072780A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713513B1 (en) 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US7713232B2 (en) 2005-11-04 2010-05-11 Medrad, Inc. System for washing and processing of cells for delivery thereof to tissue
US8182444B2 (en) 2005-11-04 2012-05-22 Medrad, Inc. Delivery of agents such as cells to tissue
US20070258886A1 (en) * 2006-04-14 2007-11-08 Celsense Inc. Methods for assessing cell labeling
EP2010646A2 (en) 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
DE102006049821A1 (de) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US20110020239A1 (en) * 2007-05-14 2011-01-27 The Johns Hopkins University Methods for in vivo imaging of cells
EP2170975B1 (en) * 2007-07-10 2018-05-02 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
CA2723171C (en) 2008-05-02 2018-03-27 Celsense, Inc. Emulsion compositions and methods for nuclear magnetic resonance and other imaging
WO2009155335A2 (en) * 2008-06-19 2009-12-23 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
JP5775815B2 (ja) * 2008-07-09 2015-09-09 コーニンクレッカ フィリップス エヌ ヴェ 複合分子ｍｒｉ及びダイナミックｐｅｔイメージングのための生理学的薬物動態解析
WO2010077671A2 (en) * 2008-12-08 2010-07-08 University Of Utah Research Foundation Stable perfluorocarbon emulsion for use as an artificial oxygen carrier
DE102009060317B4 (de) * 2009-12-23 2013-04-04 Siemens Aktiengesellschaft Kontrastmittel zur Verwendung in einem bildgebenden Verfahren zur Diagnose einer metastasierenden Tumorerkrankung und Verfahren zur Abbildung eines metastasierenden Tumorgewebes
US9606106B2 (en) 2012-02-10 2017-03-28 Children's Medical Center Corporation NMR-based metabolite screening platform
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2708244A1 (en) 2012-09-14 2014-03-19 Stichting Katholieke Universiteit Contrast agent and its use for imaging.
US10338015B2 (en) 2013-03-04 2019-07-02 The Regents Of The University Of California Methods and apparatus for analysis of sealed containers
EP2783703A1 (en) * 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
EP3077011A4 (en) * 2013-12-06 2017-06-28 Celsense Inc. Compositions and methods to image and quantify inflammation
EP3845663A1 (en) * 2016-01-21 2021-07-07 Selux Diagnostics Inc. Methods for rapid antimicrobial susceptibility testing
US9834808B2 (en) 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
US11406721B2 (en) 2016-02-22 2022-08-09 The Regents Of The University Of California Compositions and methods for imaging cell populations
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
WO2022061363A1 (en) * 2020-09-18 2022-03-24 The Regents Of The University Of California Fluorocarbon nanoemulsions and uses thereof in imaging

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094911A (en) 1969-03-10 1978-06-13 Minnesota Mining And Manufacturing Company Poly(perfluoroalkylene oxide) derivatives
JPS5127251Y2 (es) 1972-04-10 1976-07-10
US4558279A (en) * 1983-03-07 1985-12-10 University Of Cincinnati Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4570004A (en) * 1984-04-06 1986-02-11 The Board Of Regents, University Of Texas System Perfluoro crown ethers
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
IL82308A (en) 1986-06-26 1990-11-29 Ausimont Spa Microemulsions containing perfluoropolyethers
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4805916A (en) * 1987-09-14 1989-02-21 Zentner Jr John R Game of skill and coordination: ring ball
US4838274A (en) 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US4935223A (en) * 1988-08-04 1990-06-19 Board Of Regents, The University Of Texas System Labeled cells for use in imaging
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
US5539059A (en) 1988-09-28 1996-07-23 Exfluor Research Corporation Perfluorinated polyethers
IT1229222B (it) 1989-03-31 1991-07-26 Ausimont Srl Emulsioni stabili di perfluoropolieteri
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5236694A (en) 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
GB9006522D0 (en) * 1990-03-23 1990-05-23 Hider Robert C Metal complexes
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5196348A (en) * 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
DE4203254C2 (de) 1992-02-05 1996-05-02 Max Planck Gesellschaft Fluorhaltige Markierungsverbindung für NMR-Untersuchungen und deren Verwendung
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
NZ256154A (en) 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
BR9405798A (pt) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
AU6365894A (en) * 1993-03-16 1994-10-11 Alliance Pharmaceutical Corporation Fluorocarbon compositions containing a visible or fluorescent label
US5972703A (en) 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5690907A (en) * 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20020123143A1 (en) 1997-08-22 2002-09-05 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US20020016002A1 (en) 2000-01-24 2002-02-07 Jean Toma Multipotent neural stem cells from peripheral tissues and uses thereof
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
DE19830697C2 (de) 1998-07-08 2001-06-07 Metallgesellschaft Ag Verfahren zum Entfernen von relativ grobkörnigen Feststoffen aus einem stationären Wirbelbett
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
KR100968164B1 (ko) 1999-03-10 2010-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 지방 유래 간세포 및 격자
US6511967B1 (en) 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
EP1263932A4 (en) 2000-03-14 2004-06-23 Es Cell Int Pte Ltd EMBRYONIC CELLS AND NEURONAL STEM CELLS DERIVED THEREFROM
US6921632B2 (en) 2000-08-30 2005-07-26 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
US20020192688A1 (en) 2001-04-05 2002-12-19 Xiaoming Yang Imaging nucleic acid delivery
WO2003085092A2 (en) 2002-04-01 2003-10-16 Law Peter K Cellular transplantation for heart regeneration
US7357937B2 (en) 2002-09-24 2008-04-15 Therox, Inc. Perfluorocarbon emulsions with non-fluorinated surfactants
US20040109824A1 (en) 2002-12-06 2004-06-10 Hinds Kathleen Allison Particles for imaging cells
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
AU2004263136A1 (en) 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
EP1713513B1 (en) 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20060040389A1 (en) 2004-08-17 2006-02-23 Murry Charles E Purified compositions of stem cell derived differentiating cells
WO2006096499A2 (en) 2005-03-04 2006-09-14 Washington University Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t
JP4498218B2 (ja) 2005-06-03 2010-07-07 信越化学工業株式会社 含フッ素アミド化合物及びその製法
WO2007100715A2 (en) 2006-02-24 2007-09-07 Washington University Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy
US20070258886A1 (en) 2006-04-14 2007-11-08 Celsense Inc. Methods for assessing cell labeling
EP2010646A2 (en) 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
DE102007015598A1 (de) 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
US20110020239A1 (en) 2007-05-14 2011-01-27 The Johns Hopkins University Methods for in vivo imaging of cells
EP2170975B1 (en) 2007-07-10 2018-05-02 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques

Also Published As

Publication number Publication date
AU2005209169B2 (en) 2010-12-16
CA2560544C (en) 2015-05-19
US8449866B2 (en) 2013-05-28
US20130022990A1 (en) 2013-01-24
JP2007526245A (ja) 2007-09-13
EP2319544A1 (en) 2011-05-11
US20080292554A1 (en) 2008-11-27
JP5019883B2 (ja) 2012-09-05
WO2005072780A3 (en) 2006-01-26
EP1713513A2 (en) 2006-10-25
EP1713513B1 (en) 2014-06-04
CA2560544A1 (en) 2005-08-11
US8147806B2 (en) 2012-04-03
AU2005209169A1 (en) 2005-08-11
WO2005072780A2 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ES2491891T3 (es) Marcaje celular para técnicas de resonancia magnética nuclear
ES2507520T3 (es) Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático
Shi et al. An AIE‐Based Probe for Rapid and Ultrasensitive Imaging of Plasma Membranes in Biosystems
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
ES2538817T3 (es) Método para la inducción simultánea de CTL y células gamma delta T
ES2539133T3 (es) Dispositivo para mejorar la función de la válvula cardiaca
ES2484142T3 (es) Diagnóstico molecular y clasificación del melanoma maligno
WO2007120911A3 (en) Cellular labeling and quantification for nuclear magnetic resonance techniques
ES2535047T3 (es) Método para la desparafinación de una muestra tisular a base de una microemulsión
ES2524723T3 (es) Fructosil peptidil oxidasa y un sensor para analizar una proteína glucosilada
ES2560470T3 (es) Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
BRPI0412574A (pt) processo para cultivo e cultura de células
ES2546652T3 (es) Procedimiento para fabricar un cuerpo de moldeo rápidamente humectable
ES2487915T3 (es) Procedimiento para fabricar una tubería aislada usando una bolsa
ES2611736T3 (es) Encapsulamiento celular de alto rendimiento para examen o selección
EP2944964A3 (en) Lipid biomarkers for stable and unstable heart disease
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
ES2576747T3 (es) Ensayo de transferencia de energía de resonancia con un resto de sustrato de sinaptobrevina
ES2617755T3 (es) Método para diagnosticar un trastorno relacionado con hemoglobina
WO2009134435A3 (en) Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
Samkoe et al. Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
ES2564186T3 (es) Uso para fines de cribado de activos anti-envejecimiento de formas solubles de la proteína del tipo desmogleína I
ES2418459B1 (es) Relacionando agregación proteica con supervivencia de levadura
WO2006055855A3 (en) Method of imaging cell death in vivo